Discussion
The association between non-Hodgkin lymphomas and azathioprine is well documented and occurs at a frequency greater than that of chance (Doll and Kinlen, 1970 It has been suggested that lymphoproliferative disorders are more common in patients with autoimmune diseases including rheumatoid arthritis irrespective of treatment (Lea, 1964; Miller, 1967) but, in a review of the evidence, Oleinck (1967) concludes this to be unproved. A case similar to the present one was reported by Maldonado et al. (1968) in which a 7-year-old boy with pyoderma gangrenosum developed acute leukaemia after 12 months' treatment with mercaptopurine, a drug closely related to azathioprine. However, in that case there was evidence of plasma cell dyscrasia with disordered immunoglobulins during the initial illness of pyoderma gangrenosum, and the terminal illness was thought to be a plasma cell leukaemia. It seems unlikely, therefore, that the mercaptopurine was causal.
There are theoretical grounds for expecting malignant growths to arise during immunosuppression (Keast, 1970; Woodruff, 1969) and lymphomas have been produced by azathioprine experimentally in mice (Casey, 1968) . Although the association between azathioprine and acute myeloid leukaemia may be fortuitous, this is now the third case described. As there is currently an enormous increase in the use of immunosuppressive agents, particularly for non-malignant conditions, physicians should be aware of this possible grave complication. 
